EGFR and neoplasm: Other more recent treatment protocols that have been associated with a better in vitro response to chemotherapy of classical PDAC include combinations of inhibitors of MEK and EGFR (e.g., erlotinib) as well as HER3 [46,86], which enhance inhibition of cell proliferation and tumor growth, with a synergistic pro-apoptotic effect that sensitizes classical PDAC cells to chemotherapy [86].